Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Tohoku University and Astellas Establish Second Phase of Comprehensive Industry-Academia Collaboration with Aim of Creating Innovative Healthcare Solutions

09/23/2021 | 08:12pm EDT

TOKYO and Sendai, Miyagi, September 24, 2021 - Tohoku University (President; Hideo Ohno, "Tohoku University") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas" ) have established the second phase of comprehensive industry-academia collaboration on July 30 to continuously create value for patients through co-creation of innovative healthcare solutions.

In the first phase (August 2018-July 2021), Tohoku University and Astellas set up the "TACT (Tohoku University and Astellas Collaboration Committee) Office" to serve as a hub function for interorganizational open innovation. Along with building a functional network necessary to promote large-scale industry-academia collaboration, both parties have been conducting joint research mainly in the fields of medicine, pharmacy, and biomedical engineering. In the second phase of this agreement, based on the built network foundation, both parties will promote interdisciplinary joint research that will organically connect Astellas' drug discovery capabilities with Tohoku University's strengths in the medical, science, and engineering fields, and aim to create innovative healthcare solutions.

Tohoku University expects to incorporate Astellas' drug discovery capabilities for the purposes of promptly returning innovative research results to society and contributing to solving various problems, especially those in the healthcare field. In collaboration with Tohoku University, Astellas aims to realize novel healthcare solutions by obtaining early access to cutting-edge intellectual property and technology in a wide range of fields such as dentistry, science, and engineering, in addition to the fields of medicine, pharmacy, and biomedical engineering.

Based on this agreement, both parties will promote activities of collaborative creation between industry and academia to implement research results into society as value for patients.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 24 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 September 2021 00:11:11 UTC.


© Publicnow 2021
All news about ASTELLAS PHARMA INC.
10/19ASTELLAS PHARMA : Receives “2021 Award for Excellence in Corporate Disclosure”..
PU
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
DJ
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
DJ
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
DJ
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
More news
Financials
Sales 2022 1 327 B 11 688 M 11 688 M
Net income 2022 196 B 1 723 M 1 723 M
Net cash 2022 584 B 5 142 M 5 142 M
P/E ratio 2022 18,4x
Yield 2022 2,55%
Capitalization 3 627 B 31 899 M 31 957 M
EV / Sales 2022 2,29x
EV / Sales 2023 2,05x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 957,50 JPY
Average target price 2 486,15 JPY
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.22.80%31 899
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979